Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 8/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382222 | 0.92 | MCHR2 (0.62) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL1587467 | 0.86 | MCHR2 (0.61) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL1586959 | 0.86 | MCHR2 (0.61) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL15160320 | 0.83 | MCHR2 (0.57) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL4233076 | 0.83 | SIGMAR1 (0.58) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL3810405 | 0.83 | FFAR1 (0.67) | MCHR2MCHR1FFAR1 | |
| SCHEMBL3812702 | 0.82 | MCHR2 (0.65) | MCHR2MCHR1FFAR1 | |
| SCHEMBL15158647 | 0.80 | MCHR2 (0.54) | MCHR2MCHR1FFAR1 | |
| SCHEMBL15494625 | 0.79 | MCHR2 (0.56) | MCHR2MCHR1FFAR1SIGMAR1 | |
| SCHEMBL6848540 | 0.78 | MCHR2 (0.60) | MCHR2MCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | claimed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| EP-2033644-A1 | Spiroindene and spiroindane compounds | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| EP-1385514-A4 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-04-13 | — | — | EP | disclosed |
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | disclosed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | MCHR2 3278/4885MCHR1 2895/4885FFAR1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.